Pregled bibliografske jedinice broj: 745120
Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys
Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys // Combined EPC & IAP Meeting
Southampton, Ujedinjeno Kraljevstvo, 2014. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 745120 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys
Autori
Hauser, Goran ; Milošević, Marko ; Giljača, Vanja ; Benjak, Indira ; Bulić, Zlatko ; Štimac, Davor
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
Combined EPC & IAP Meeting
Mjesto i datum
Southampton, Ujedinjeno Kraljevstvo, 24.06.2014. - 28.06.2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
acute pancreatitis; ERCP
Sažetak
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common major complication of ERCP. In some cases pancreatitis is followed by severe course with pancreatic necrosis and multiorgan failure. Diclophenac potassium together with indometacine is currently standard treatment in prevention of PEP while ceftazidime is possible alternative treatment for patients with contraindication for nonsteroidal antiimflammatory drugs (NSAID).
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
